Mechanisms of hypertension after renal transplantation

Current Opinion in Urology

Volumn 10, Issue 2, 2000, Pages 81-86

  Rosenkranz, Alexander R ^a   Mayer, Gert ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CREATININE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; TACROLIMUS;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CREATININE BLOOD LEVEL; DIFFERENTIAL DIAGNOSIS; GRAFT FAILURE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; CREATININE; GRAFT REJECTION; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS;

EID: 0034027356     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200003000-00006     Document Type: Review

References (65)

1. 1 Barnas U, Mayer G. Hypertension after renal transplantation [in German]. J Hypertonie 1996; 1:16-21.
2. 2 Zeier M, Mandelbaum A, Ritz E. Hypertension in the transplanted patient. Nephron 1998; 80:257-268. This paper elegantly discusses, on the basis of case reports, the mechanisms and management of hypertension in renal transplant patients, and therefore gives a good, clinically orientated overview.
3. 3 Peschke B, Scheuermann EH, Geiger H, Bölscher S, Kachel H-G, Lenz T. Hypertension is associated with hyperlipidemia, coronary heart disease and chronic graft failure in kidney transplant recipients. Clin Nephrol 1999; 51:290-295. The results of this study further support the view that hypertension may be a risk factor for the development of chronic renal graft failure and coronary artery disease in kidney transplant recipients.
4. 4 Sanders CE, Curtis JJ. Role of hypertension in chronic renal allograft dysfunction. Kidney Int 1995; 48(Suppl 52):S43-S47.
5. 5 Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Kidney Int 1998; 53:217-222. In this paper, Cox regression analysis established increased blood pressure as an independent risk factor for graft failure. The authors concluded that post-transplant blood pressure is a highly significant predictor of long-term kidney graft outcome.
6. 6 Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999; 33:829-839. Against a background of increasing costs in the health care system, this is the first paper estimating the costs on the treatment of renal transplant patients.
7. 7 Rettig R, Folberth C, Stauss H, Kopf D, Waldherr R, Unger T. Role of the kidney in primary hypertension: a renal transplantation study in rats. Am J Physiol 1990; 258:F606-F611.
8. 8 Kopf D, Waldherr R, Rettig R. Source of kidney determines blood pressure in young renal transplanted rats. Am J Physiol 1993; 265:F104-F111.
9. 9 Rettig R, Folberth C, Stauss H, Kopf D, Waldherr R, Baldauf G. Hypertension in rats induced by renal grafts from renovascular hypertensive donors. Hypertension 1990; 15:429-435.
10. 10 Curtis JJ, Luke RG, Dustan HP, Kashgarian M, Whelchel JD, Jones P, et al. Remission of essential hypertension after renal transplantation. N Engl J Med 1983; 309:1009-1014.
11. 11 Guidi E, Bianchi G, Rivolta E. Hypertension in men with a kidney transplant: role of familial versus other factors. Nephron 1985; 41:14-21.
12. 12 Strandgaard S, Hansen U. Hypertension in renal allograft recipients may be conveyed by cadaveric kidneys from donors with subarachnoidal hemorrhage. Br Med J 1986; 292:1041-1044.
13. 13 Braun WE. Long term complications of renal transplantation. Kidney Int 1990; 37:1363-1378.
14. 14 Yasamura T, Oka T, Aikawa Y, Ohmori Y, Nakane Y. Beneficial effect of bilateral nephrectomy on long term survival of living related kidney allografts. Transplant Proc 1989; 21:1967-1969.
15. 15 Midtvedt K, Hartmann A, Bentdal O, Brekke IB, Fauchald P. Bilateral nephrectomy simultaneously with renal allografting does not alleviate hypertension 3 months following living donor transplantation. Nephrol Dial Transplant 1996; 11:2045-2049.
16. 16 Fricke L, Doehn C, Steinhoff J, Sack K, Jocham D, Fornara P. Treatment of posttransplant hypertension by laparoscopic bilateral nephrectomy. Transplantation 1998; 65:1182-1187.
17. 17 Aeberhard JM, Schneider PA, Valloton MB, Kurtz A, Leski M. Multiple site estimates of erythropoietin and renin in polycythemic kidney transplant patients. Transplantation 1990; 50:613-616.
18. 18 Schwarzbeck A, Wittenmeier KW, Hällfritzsch U. Anaemia in dialysis patients as a side effect of sartanes [letter]. Lancet 1998; 352:286.
19. 19 Merkus JW, Huysmanns FT, Hoitsma AJ, Buskens FG, Skotnicki SH, Koene RA. Renal allograft artery stenosis: results of medical treatment and intervention. A prospective analysis. Transplant Int 1993; 6:111-115.
20. 20 Fontan MP, Rodriguez-Carmona A, Falcon TG, Rivera CF, Valdes F. Early immunologic and nonimmunologic predictors of arterial hypertension after renal transplantation. Am J Kidney Dis 1999; 33:21-28. In this interesting study, the authors demonstrated that primarily nonimmunologic risk factors determine the graft prognosis, namely hypertension, grafting of the right kidney, elderly or female donor, and markers of earty ischaemia-reperfusion injury.
21. 21 Sankari BR, Geisinger M, Zelch M, Brouhard B, Cunningham R, Novick AC. Posttransplant renal artery stenosis: impact of therapy on long-term kidney function and blood pressure control. J Urol 1996; 155:1860-1864.
22. 22 Fung LC, McLorie GA, Khoury AE, Churchill BM. Donor aortic cuff reduces the rate of anastomotic arterial stenosis in pediatric renal transplantation. J Urol 1995; 154:909-913.
23. 23 Monsour HP, Wood RP, Dyer CH, Galati JS, Ozaki CF, Clark JH. Renal insufficiency and hypertension as long term complications in liver transplantation. Semin Liver Dis 1995; 15:123-132.
24. 24 Haas M, Mayer G. Cyclosporine A associated hypertension: pathomechanisms and clinical consequences. Nephrol Dial Transplant 1996; 12:395-398.
25. 25 Meyer-Lehnert H, Schrijer RW. Potential mechanism of cyclosporine A induced vascular smooth muscle contraction. Hypertension 1989; 133:352-360.
26. 26 Lau DCW, Wong KL, Hwang WS. Cyclosporine toxicity on cultured rat microvascular endothelial cells. Kidney Int 1989; 35:604-613.
27. 27 Zoja C, Furci L, Ghilardi F, Zilo P, Benigni A, Remuzzi G. Cyclosporine induced endotheial cell injury. Lab Invest 1986; 55:455-462.
28. 28 Marsen TA, Simonson MS, Dunn MJ. Thrombin mediated ET1 gene regulation involves CaM kinases and calcineurin in human endothelial cells. J Cardiovasc Pharmacol 1995; 26 (Suppl 3):S1-S4.
29. 29 Mouquet C, Benalia H, Carayon A, Bitker MO, Luciani J, Viars P. Is the vasoconstrictive effect of cyclosporine mediated by endothelin in kidney transplantation? Transplant Proc 1994; 26:277-278.
30. 30 Grieff M, Loertscher RE, Shohaib SA, Stewart DJ. Cyclosporine-induced elevation in circulating endothelin-1 in patients with solid organ transplants. Transplantation 1993; 56:880-884.
31. 31 Sturrock ND, Lang CC, MacFarlane LJ, Dockrell ME, Ryan M, Webb DJ, et al. Serial changes in blood pressure, renal function, endothelin and lipoprotein (a) during the first 9 days of cyclosporin therapy in males. J Hypertens 1995; 13:667-673.
32. 32 Kon V, Sugiura M, Inagami T, Bradley RH, Ichikawa I, Hoover RL. Role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int 1990; 37:1487-1491.
33. 33 Takeda Y, Miyamori I, Wu P, Furukawa K, Inabe S, Takeda R, et al. Effect of FK 506 on the expression of endothelin receptor mRNA in the vasculature. J Cardiovasc Pharmacol 1995; 26(Suppl 3):S290-S292.
34. 34 Asberg A, Attramadal H, Midtvedt K, Sund S, Hartmann A, Berg KJ. Gene expression of the renal endothelin system in renal transplant recipients on cyclosporine A based immunosuppression. Transplantation 1999; 67:1056-1060.
35. 35 Waldman S, Murad F. Cyclic GMP synthesis and function. Pharmacol Rev 1987; 39:183-196.
36. 36 Schmidt HHHW, Klein MM, Niromomand F, Böhme H. Is arginine a physiological precursor of endothelium derived nitric oxide? Eur J Pharmacol 1988; 148:293-295.
37. 37 Rego A, Vargas R, Wroblewska B, Foegh ML, Ramwell PW. Attenuation of vascular relaxation and cyclic GMP responses by cyclosporine A. J Pharmacol Exp Ther 1990; 252:165-170.
38. 38 Huang LQ, Witworth JA, Chesterman CN. Effects of cyclosporine and dexamethasone on hemostatic and vasoactive functions of vascular endothelial cells. Blood Coag Fibrin 1995; 6:438-445.
39. 39 Penner B, Jeffrey J, Smyth D. Cyclosporine induced nephrotoxicity in the rat: the effect of a1-adrenoreceptor blockade with prazosin. Transplantation 1993; 56:1569-1572.
40. 40 Curtis JJ, Luke JG, Jones P, Diethelm AG. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med 1988; 85:134-138.
41. 41 Sturrock ND, Lang CC, Coutie WJ, Struthers AD. Cyclosporin induced renal vasoconstriction is augmented by frusemide and angiotensin II in humans. J Hypertens 1995; 13:987-991.
42. 42 Lafayette R, Mayer G, Meyer TW. The effects of blood pressure reduction on cyclosporine nephrotoxicity in the rat. J Am Soc Nephrol 1993; 3:1892-1899.
43. 43 Shihab FS, Bennet WM, Tanner AM, Andoh TF. Angiotensin II blockade decreases TGF-b1 and matrix proteins in cyclosporine nephropathy. Kidney Int 1997; 52:660-673.
44. 44 Kurtz A, Delia Bruna R, Kühn KW. Cyclosporine A enhances renin secretion and production in isolated juxtaglomerular cell. Kidney Int 1988; 33:947-953.
45. 45 Bantle JP, Boudreau RJ, Ferris TF. Suppression of plasma renin activity by cyclosporine. Am J Med 1987; 83:59-64.
46. 46 Stanek B, Kovarik J, Raoul-Rockenschaub S, Silberbauer K. Renin angiotensin aldosterone system and vasopressin in cyclosporine treated renal allograft recipients. Clin Nephrol 1987; 28:186-189.
47. 47 Gardiner DS, Watson MA, Junor BJR, Briggs JD, More IAR, Lindop GBM. The effect of conversion from cyclosporin to azathioprine on renin-containing cells in renal allograft biopsies. Nephrol Dial Transplant 1991; 6:363-367.
48. 48 Regitz-Zagrosek V, Auch-Schwelk W, Hess B, Klein U, Duske E, Steffen C, et al. Tissue and subtype specific modulation of angiotensin II receptors by chronic treatment with cyclosporine A, angiotensin converting enzyme inhibitors and AT1 antagonists. J Cardiovasc Pharmacol 1995; 26:66-72.
49. 1.
50. 50 Shihab FS, Tanner AM, Shao Y, Weffer MI. Expression of TGF-beta 1 and matrix proteins is elevated in rats with chronic rejection. Kidney Int 1996; 50:1904-1913.
51. 51 Border WA, Noble NA. Interactions of transforming growth factor-b and angiotensin II in renal fibrosis. Hypertension 1998; 31:181-188.
52. 52 Gellai M. Physiological role of endothelin in cardiovascular and renal hemodynamics: studies in animals. Curr Opin Nephrol Hypertens 1997; 6:64-68.
53. 53 Wlliams R, Neuhaus P, Bismuth H, McMaster P, Pichlmayr R, Calne R, et al. Two year data from from the European multicenter tacrolirnus (FK506) liver study. Transplant Int 1996; 9(Suppl 1):S144-S150.
54. 54 Radermacher J, Meiners M, Bramlage C, Kliem V, Behrend M, Schlitt HJ, et al. Pronounced renal vasoconstriction and systemic hypertension in renal transplant patients treated with cyclosporin A versus FK 506. Transplant Int 1998; 11:3-10.
55. 55 Ellis D, Gabriel ME, Ellis MP. Phospholipase C and Na-K ATPase activation by cyclosporine and FK506 in LLC-PK1 cells. Transplantation 1991; 52:349-353.
56. 56 Gerhart U, Riedasch M, Hohage H. Blood pressure control in kidney transplant recipients: influence of immunosuppression. J Auton Pharmacol 1999; 19:49-54.
57. 57 Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis for randomised trials. Br Med J 1999; 318:1104-1107. This paper summarizes four different studies on tacrolimus versus cyclosporine, showing a significant reduction in acute rejection for tacrolimus. This work does not include data on long-term renal graft survival.
58. 58 Taler SJ, Textor SC, Cancanello VJ, Wilson DJ, Wiesner RH, Krom RA. Loss of nocturnal blood pressure fall after liver transplantation during immunosupressive therapy. Am J Hypertens 1995; 8:598-605.
59. 59 Lyson T, Ermel LD, Belshaw PJ, Alberg DG, Schreiber SL, Victor RG. Cyclosporine-and FK506-induced sympathetic activation correlates with calcineurin mediated inhibition of T cell signalling. Circ Res 1993; 73:596-602.
60. 60 Groth CG, Bäckman L, Morales J-M, Calne R, Kreis H, Lang P, et al. Sirolimus (Rapamycin) based therapy in human renal transplantation. Transplantation 1999; 67:1036-1042. This is the latest study on rapamycin to suggest that this substance can be used as base therapy in the prophylaxis of acute renal transplant rejection.
61. 61 Witworth JA, Brown MA, Kelly JJ, Williamson PM. Experimental studies on corticoid induced hypertension in humans. J Hum Hypertens 1995; 9:395-399.
62. 62 Hricik DE, Lautman J, Bartucci MR, Moir EJ, Mayes JT, Schulak JA. Variable effects of steroid withdrawal on blood pressure reduction in cyclosporine treated renal transplant recipients. Transplantation 1992; 53:1232-1239.
63. 63 Taler SJ, Textor SC, Canzanello VJ, Schwartz L, Porayko M, Wiesner RH, et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus and cyclosporine. Transplantation 1996; 62:1588-1592.
64. 64 Punch JD, Shieck VL, Campbell DA, Bromberg JS, Turcotte JG, Merion RM. Corticosteroid withdrawal after liver transplantation. Surgery 1995; 118:783-786.
65. 65 Kupin W, Venkat KK, Oh HK, Dienst S. Complete replacement of methylprednisolone by azathioprine in cyclosporine treated primary cadaveric renal transplant recipients. Transplantation 1988; 45:53-55.